智通财经网·2026-02-09 08:41Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Glucosamine Sulfate Capsules, which are primarily used for treating primary and secondary osteoarthritis [1] Company Summary - The company submitted the application for the marketing authorization of Glucosamine Sulfate Capsules to the National Medical Products Administration in August 2024, and the application was accepted [1] - The drug received its registration certificate in February 2026, with the review conclusion being approval for registration [1] Industry Summary - Glucosamine Sulfate Capsules are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [1] - The sales revenue for Glucosamine Sulfate Capsules in Chinese public medical institutions is estimated to be approximately RMB 850 million in 2024 [1]